Front. Immunol. Frontiers in Immunology Front. Immunol. 1664-3224 Frontiers Media S.A. 10.3389/fimmu.2023.1163550 Immunology Correction Corrigendum: The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studies Goll Johannes B. 1 † Bosinger Steven E. 2 3 4 5 † Jensen Travis L. 1 Walum Hasse 2 Grimes Tyler 1 Tharp Gregory K. 4 Natrajan Muktha S. 5 6 Blazevic Azra 7 Head Richard D. 8 Gelber Casey E. 1 Steenbergen Kristen J. 1 Patel Nirav B. 4 Sanz Patrick 9 Rouphael Nadine G. 5 6 10 Anderson Evan J. 10 11 Mulligan Mark J. 5 6 10 12 * † Hoft Daniel F. 7 13 * † 1 Department of Biomedical Data Science and Bioinformatics, The Emmes Company, LLC, Rockville, MD, United States 2 Division of Microbiology & Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, United States 3 Department of Pathology & Laboratory Medicine, School of Medicine, Emory University, Atlanta, GA, United States 4 Emory NPRC Genomics Core, Emory National Primate Research Center, Emory University, Atlanta, GA, United States 5 Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, United States 6 Hope Clinic of the Emory Vaccine Center, Emory University, Atlanta, GA, United States 7 Division of Infectious Diseases, Allergy, and Immunology, Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, MO, United States 8 McDonnell Genome Institute, Washington University, St. Louis, MO, United States 9 Office of Biodefense, Research Resources and Translational Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, United States 10 Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Emory University, Atlanta, GA, United States 11 Center for Childhood Infections and Vaccines (CCIV) of Children’s Healthcare of Atlanta and Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States 12 New York University Vaccine Center, New York, NY, United States 13 Department of Molecular Microbiology & Immunology, Saint Louis University, St. Louis, MO, United States

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

*Correspondence: Daniel F. Hoft, Daniel.Hoft@health.slu.edu; Mark J. Mulligan, mark.mulligan@nyulangone.org

†These authors have contributed equally to this work

This article was submitted to Systems Immunology, a section of the journal Frontiers in Immunology

 23 02 2023 2023 14 1163550 10 02 2023 13 02 2023 Copyright © 2023 Goll, Bosinger, Jensen, Walum, Grimes, Tharp, Natrajan, Blazevic, Head, Gelber, Steenbergen, Patel, Sanz, Rouphael, Anderson, Mulligan and Hoft 2023 Goll, Bosinger, Jensen, Walum, Grimes, Tharp, Natrajan, Blazevic, Head, Gelber, Steenbergen, Patel, Sanz, Rouphael, Anderson, Mulligan and Hoft

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A corrigendum on The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studies by Goll JB, Bosinger SE, Jensen TL, Walum H, Grimes T, Tharp GK, Natrajan MS, Blazevic A, Head RD, Gelber CE, Steenbergen KJ, Patel NB, Sanz P, Rouphael NG, Anderson EJ, Mulligan MJ and Hoft DF (2023) Front. Immunol. 13:1093242. doi: 10.3389/fimmu.2022.1093242 RNA-Seq statistical power ERCC tularemia vaccine (DVC-LVS) gene filtering sequencing depth read length reproducibility

In the published article, there was an error in the Figure 7 legend as published. The figure legend effect size values were incorrectly displayed as “>1.25, 51.5, 51.75, 52” instead of “>1.25, ≥1.5, ≥1.75, ≥2”. The corrected Figure 7 and its caption appear below.

Relative power by sample size, effect size, and sequencing depth at each post-vaccination day as simulated using the modified PROPER R package. Days were sorted by decreasing vaccination effect based on overall fold changes and DEG responses observed for this study (see Figure 3A). Power was assessed for different fold-change cutoffs (indicated by color-coded lines), sequencing depth (as indicated by the line type), and sample size (x-axis).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.